Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab for pure red cell aplasia after major ABO-mismatched allogeneic HSCT
2021-000932-70Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of isatuximab in pure red cell aplasia (PRCA) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Time to transfusion independence / PRCA resolution. Started Sep 2021; status: active.
02
Drugs
isatuximab
03
Conditions
pure red cell aplasia (PRCA)
Beyond the preview
Go deeper on 2021-000932-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000932-70.